Primary lateral sclerosis (PLS) is a motor neuron disease that occurs when the nerve cells in muscles slowly deteriorate. This leads to weakness in the voluntary muscles like the tongue ...

MNDs are neurological disorders that destroy motor neurons, the cells that control skeletal muscle activity such as walking, breathing, speaking, and swallowing.

The Global Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 634 Million in 2023 and expected to grow USD 1021 Million in 2032.

Motor neuron disease usually refers to amyotrophic lateral sclerosis, but it can also refer to other kind of neurodegenerative disease that affect the motor neurons, such as progressive primary ...

In a small human trial in SMA patients neurostimulation sessions improved motoneuron function, reduced fatigue, and improved leg muscle strength and walking.

The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Ncardia, a global leader in human induced pluripotent stem cell (hiPSC) technology, today announced the launch of Ncyte® ...

A 3D model accurately mimicking the Blood-Brain Barrier (BBB) in a laboratory environment has been successfully developed by ...

Methods Cohort recruited via a specialist, multidisciplinary clinic. Patients were categorised into four clinical phenotypes (ALS, flail arm, flail leg and primary lateral sclerosis) according to site ...

Compared to placebo, the study did not meet the primary endpoint of efficacy in slowing disease progression. The primary endpoint was evaluated as a change in disease severity over time as ...